GSK PLC agreed to pay up to $3.3 billion to acquire vaccine maker Affinivax Inc., in a deal that would hand thea new vaccine technology targeting common bacterial diseases such as meningitis and pneumonia.
The British pharmaceutical company, formerly known as GlaxoSmithKline, said it would pay $2.1 billion upfront to buy the Boston-based company, with a further $1.2 billion in what it called milestone payments if Affinivax meets certain goals.
لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر: